Program
nurandociguat
Also written as “BAY3283142”, “Nurandociguat (BAY3283142) old tablet - SD” and “Nurandociguat (BAY3283142) new tablet - SD”.
Its studies are mostly in Renal Insufficiency, Chronic · Coronary Artery Disease, led by Bayer.
Drug pageNurandociguat: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayer | 91 open or running | phase 2since Jul 22, 2024 | Jul 28, 2022 | May 7, 2027phase 1 · NCT07431294 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jul 28, 2022First study: phase 1 study in Renal Insufficiency, ChronicFirst studyNCT05515432 · 45 enrolled · Germany
- Aug 5, 2022Phase 1 study in Renal Insufficiency, ChronicNCT05491642 · 56 enrolled · Bulgaria, Germany
- Mar 24, 2023Phase 1 study in Renal Insufficiency, ChronicNCT05800444 · 24 enrolled · Japan
- Feb 29, 2024Named nurandociguatINNProposed as its International Nonproprietary Name in WHO's List 130 · before, BAY3283142
- May 3, 20242 phase 1 studies in Renal Insufficiency, ChronicNCT06402721, NCT06428825
- Jun 24, 2024Phase 1 study in Renal Insufficiency, ChronicNCT06487845 · 24 enrolled · China
- Jul 22, 2024Phase 2 study in Renal Insufficiency, ChronicNCT06522997 · 1,222 enrolled · United States, Argentina, Belgium and more
- Feb 16, 2026Phase 1 study in Stable Coronary Artery DiseaseNCT07431294 · 36 planned · Bulgaria, Germany
- Jul 17, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07722585 · 16 enrolled · Germany
Ahead
- May 7, 2027Primary completion: phase 1 study in Stable Coronary Artery DiseaseNCT07431294
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07722585Renal Insufficiency, Chronic · Germany | 1 | Completed | Oct 12, 2026 | 16 |
| NCT07431294Stable Coronary Artery Disease · Bulgaria, Germany | 1 | Not yet recruiting | May 7, 2027 | 36 |
| NCT06522997Renal Insufficiency, Chronic · United States, Argentina, Belgium and more | 2 | Completed | Oct 24, 2025 | 1,222 |
| NCT06487845Renal Insufficiency, Chronic · China | 1 | Completed | Sep 19, 2024 | 24 |
| NCT06428825Renal Insufficiency, Chronic · Germany | 1 | Completed | Nov 21, 2025 | 75 |
| NCT06402721Renal Insufficiency, Chronic · United States | 1 | Completed | Feb 24, 2025 | 24 |
| NCT05800444Renal Insufficiency, Chronic · Japan | 1 | Completed | Jul 19, 2023 | 24 |
| NCT05491642Renal Insufficiency, Chronic · Bulgaria, Germany | 1 | Completed | Jan 3, 2023 | 56 |
| NCT05515432Renal Insufficiency, Chronic · Germany | 1 | Completed | Mar 7, 2023 | 45 |
How it is read
Names in the registry
- “BAY3283142”, 6 entries
- “Nurandociguat (BAY3283142) old tablet - SD”, 1 entry
- “Nurandociguat (BAY3283142) new tablet - SD”, 1 entry
- “Nurandociguat (BAY3283142) old tablet”, 1 entry
- “Nurandociguat (BAY3283142) new tablet”, 1 entry
Codes read as this program: BAY3283142.
Conditions, from the studies’ own filings
- Renal Insufficiency, Chronic, 8 studies
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.